Natera Inc.
Natera Reports Strong Q1 2025 Financial Results
Summary
Natera, Inc. reported robust financial results for the first quarter of 2025, with total revenues of $501.8 million, representing a 36.5% increase from the same period in 2024. The company achieved a gross margin of 63.1%, up from 56.7% in the first quarter of 2024, driven by higher revenues and cost reductions. Natera processed approximately 855,100 tests, a 16.2% increase from the previous year, and performed around 167,700 oncology tests, a 46.1% increase. Despite a net loss of $66.9 million, the company generated positive cash flow of $23.2 million for the quarter. Natera anticipates 2025 total revenue between $1.94 billion and $2.02 billion, with a gross margin of approximately 60% to 64% of revenues.
Profitelligence Alerts
Get alerts for NTRA
Be first to know when Natera Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Natera Inc.
Natera Inc., a leading player in the life sciences and diagnostics industry, specializes in developing cell-free DNA testing technologies. This biotechnological firm primarily focuses on non-invasive genetic testing, assisting in maternal-fetal medicine through the screening of high-risk pregnancies with its flagship product, Panorama. In addition to prenatal screening, Natera offers genetic solutions for oncology and organ health, providing critical insights through its comprehensive suite of products. These offerings are especially significant in cancer diagnostics, where Natera's technology helps in early detection, monitoring, and guiding treatment options. The company's innovative approach to DNA analysis enables the identification of genetic conditions and the monitoring of health trends with precision and ease, impacting healthcare providers, patients, and researchers. With its headquarters in San Carlos, California, Natera Inc. is at the forefront of genetic testing advancements, playing a pivotal role in personalizing medicine and revolutionizing patient care by enhancing early diagnosis capabilities and improving clinical outcomes.
Official SEC Documents
Advertisement